WADA - Anti-doping testing figures

202 April 2 2024 Anti-Doping Testing Figures Please click on the sub-report title to access it directly. To print, please insert the pages indicated below. Executive Summary – pp. 2-9 (7 pages) Laboratory Report – pp. 10-39 (30 pages) Sport Report – pp. 40-155 (116 pages) Testing Authority Report – pp. 156-279 (124 pages) ABP Report-Blood Analysis – pp. 280-320 (41 pages) 2022 Anti-Doping Testing Figures World Anti-Doping Agency 202 Anti-Doping Testing Figures 2

EXECUTIVE SUMMARY

2022 Anti-Doping Testing Figures 2022 Anti-Doping Testing Figures Samples Analyzed and Reported by Accredited and Approved Laboratories in ADAMS EXECUTIVE SUMMARY This Executive Summary is intended to assist stakeholders in navigating the data outlined within the 2022 Testing Figures Report (2022 Report) and to highlight overall trends. The 2022 Report summarizes the results of all the samples WADA-accredited Laboratories analyzed and reported into WADA’s Anti-Doping Administration and Management System (ADAMS) in 2022. This is the second set of global testing figures under the version of the World Anti-Doping Code (Code) that came into effect in January 2021. The 2022 Report – which includes this Executive Summary and subreports by Laboratory, Sport, Testing Authority (TA) and Athlete Biological Passport (ABP) Blood Analysis – includes inand out-of-competition urine samples; blood, dried blood spot (DBS) and ABP blood data; and the resulting Adverse Analytical Findings (AAFs) and Atypical Findings (ATFs). The 2022 Testing Figures Report only focuses on Signatory anti-doping data that is reported into ADAMS and no longer includes data that is not reported into ADAMS.

REPORT HIGHLIGHTS

• Overall Samples: A 6.4% increase in the total number of samples (including urine, non-ABP blood and DBS samples) analyzed and reported into ADAMS in 2022 vs 2021. • %AAF: An increase in the total percentage of AAFs: 0.65% in 2021 to 0.77% in 2022. • Labs: An increase in the total number of samples analyzed and reported by most WADAaccredited laboratories and WADA-approved laboratories into ADAMS in 2022 vs 2021. • Non-ABP Blood Samples: An increase in the total number and percentage of non-ABP blood and DBS samples analyzed in 2022. • ABP blood Samples: An increase of 1.4% in the number of ABP blood samples analyzed in 2022. • Tests: An increase in the total number of AAFs and %AAF for ERAs [including erythropoietin

(EPO) and other EPO-receptor agonists], GHRFs and GC/C/IRMS tests in 2022. USE OF ADAMS ADAMS continues to be a critical data-gathering tool for the anti-doping community. The figures of urine, blood, dried blood spot (DBS) and ABP samples were compiled according to the ‘Sample Collection Date’ (and not the WADA-accredited Laboratory’s ‘Sample Reception Date’). The data was compiled using sample collection dates between 1 January and 31 December 2022. In addition, in 2022, WADA adjusted Anti-Doping Organization (ADO) and Delegated Third Party (DTP) accounts to ensure the ADAMS account structure reflects the 2021 Code. Under the 2021 Code, only a Signatory can act as the Testing Authority (TA) or Results Management Authority (RMA). Therefore, changes were incorporated into the ADAMS reporting process to ensure that only laboratory results that fall under the World Anti-Doping Program (e.g., only tests where a Signatory ADO is the Testing

Authority) were reported in ADAMS. The results from laboratory testing of samples from non-signatories are no longer reported in ADAMS. Page 1 of 7 2022 Anti-Doping Testing Figures – Executive Summary 2022 Anti-Doping Testing Figures Samples Analyzed and Reported by Accredited and Approved Laboratories in ADAMS OVERALL FINDINGS The 2022 data shows an increase of 6.4% in the number of overall samples analyzed from 241,430 in 2021 to 256,769 in 2022. There was an increase in the percentage of total findings (AAFs and ATFs - combined) from 0.77% in 2021 to 0.93 in 2022. In addition, the data shows an increase in the percentage of AAFs – more commonly known as positive tests – from 0.65% in 2021 to 0.77% in 2022. In 2022, the proportion of ATFs reported (394 ATFs in 256,769 samples) increased relative to 2021 (312 ATFs in 241,430 samples). %AAF 2012-2022 (ADAMS) 4.0 3.35 3.0 3.06 2.95 2.68 2.73 2.70 2.60 2.32 % 2.0 2.01 1.78 1.59 1.24 1.22 1.32 1.0 0.99 0.97 01 .7.0 75 01 .. 81 30 1.00 01 .. 71 73 01 .. 70 55 00 .. 69 77 0.67 0.65 0.77 0.56

0.48 0.49 0.0 % AAF% AAF% AAF% AAF% AAF% AAF% AAF% AAF% AAF% AAF% AAF

2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Olympic Sports Non-Olympic Sports Overall The results also show an increase in the number of (non-ABP) blood samples analyzed from 22,398 (blood + DBS samples) in 2021 to 25,456 (blood + DBS samples) in 2022. Page 2 of 7 2022 Anti-Doping Testing Figures – Executive Summary 2022 Anti-Doping Testing Figures Samples Analyzed and Reported by Accredited and Approved Laboratories in ADAMS IMPLEMENTATION OF ABP Blood ABP The number of International Federations (IFs) that included ABP blood testing was 25 in 2022 (compared to 26 in 2021) while the number of National Anti-Doping Organizations (NADOs) increased from 72 in 2021 to 78 in 2022. The total number of ABP samples increased by 1.4% compared to 2021 (30,821 in 2021 to 31,246 in 2022). Steroidal ABP The gas chromatography combustion isotope ratio mass spectrometry (GC/C/IRMS) analytical method is an important test connected to the steroidal module of the ABP for urine samples. IRMS can be triggered by the ABP or requested by the Testing Authority (TA) based on other information. The number of AAFs and the % AAFs from the application of this method has increased compared to 2021 (93 in 2021 and 99 in 2022) while the number of tests has increased in 2022 by 4% (4,422 in 2021 versus 4,602). Based on the relative percentage of AAFs in comparison to other methods, the application of the GC/C/IRMS test continues, at 2.15% AAF, to be the analytical method with the highest proportion of AAFs. Page 3 of 7

2022 Anti-Doping Testing Figures – Executive Summary 2022 Anti-Doping Testing Figures Samples Analyzed and Reported by Accredited and Approved Laboratories in ADAMS COMPLIANCE WITH THE TDSSA The 2022 Report marks the eighth year that Anti-Doping Organizations (ADOs) were required to incorporate the Technical Document for Sport Specific Analysis (TDSSA) into their testing programs. The TDSSA is intended to ensure that three groups of prohibited substances ((Erythropoietin Receptor Agonists (ERAs), Growth Hormone (GH) and GH Releasing Factors (GHRFs)), which are deemed to be at risk of abuse in certain sports/disciplines, are subject to an appropriate and consistent Minimum Level of Analysis by all ADOs. From 2015 to 2022, there has been an overall increase in testing when compared to 2014 (the year prior to TDSSA implementation) including: • An increase in the recording of TDSSA compliant sports/disciplines in ADAMS. • A very slight decrease in total (urine and blood) ERAs analysis, an increase in total AAFs reported, and increase in percentage of ERA AAFs. • An increase in total GH analysis between 2021 and 2022 and a decrease in the number of GH AAFs reported (7 cases in 2021, including one GH biomarker AAF, versus 5 cases in 2022). • A decrease in GHRFs analysis between 2021 and 2022 but an increase in the number of AAFs. Erythropoietin-Receptor Agonists (ERAs) ERAs ERAs Blood AAFs AAFs Year AAFs Total # of Sports # of TAs Urine Tests Tests Urine Blood 2022 51,678 3,776 66 7 73 151 257 2021 50,940 4,953 52 14 66 100 217 2020 35,963 1,845 29 3 32 102 197

2019 51,929 3,757 78 14 92 120 243 2018 47,955 4792 61 16 77 118 229 2017 44,322 4531 56 29 85 116 220 2016 43,246 3464 44 22 66 108 212 2015 32,999 3219 45 1 46 94 183 Growth Hormone (GH) GH Isoforms GH Biomarkers Year AAFs Total # of Sports # of TAs Tests Tests 2022 16,680 4,500 5 119 144 2021 14,734 4,720 7 84 130 2020 7,509 2,855 1 82 114 2019 17,393 6,790 6 103 156 2018 15,487 8,755 2 99 137 2017 13,474 7,008 0 90 124 2016 11,555 5,983 6 68 111 2015 11,082 2,182 4 74 103 1 AAF from GH Biomarker Test Growth Hormone Releasing Factors (GHRFs) Year GHRFs Urine Tests AAFs Total # of Sports # of TAs 2022 56,885 14 161 245 2021 65,170 7 104 222 2020 46,341 13 102 199 2019 66,990 26 126 234 2018 60,964 21 124 231 2017 57,869 19 119 218 2016 42,730 15 111 207 2015 21,654 14 88 145 Page 4 of 7 2022 Anti-Doping Testing Figures – Executive Summary 2022 Anti-Doping Testing Figures

Samples Analyzed and Reported by Accredited and Approved Laboratories in ADAMS ADVERSE ANALYTICAL FINDINGS The 2022 Report does not detail statistics on Anti-Doping Rule Violations (ADRVs). These results are included in a separate ADRVs Report, which details analytical and non-analytical cases and the outcomes of results management. The 2022 ADRVs Report will be published in 2024. The figures include all analyses conducted in 2022 by the WADA-accredited Laboratories and by the WADA-approved Laboratories (approved by WADA to conduct blood analysis exclusively for the purposes of the ABP blood module). In reading the 2022 Report, it is important to note that: • One single result does not necessarily correspond to one athlete. Results may correspond to multiple findings regarding the same athlete or measurements performed on the same athlete, such as in the case of longitudinal studies of testosterone. • The number of AAFs in the Report may not correspond with the number of ADRVs reported by ADOs. This is because all results are subject to a results management process conducted by ADOs, which includes matching results with Therapeutic Use Exemptions (TUEs) and/or longitudinal studies, which can result in no sanction. • To help with the interpretation of the 2022 Report, a comprehensive Question and Answer document is available on WADA’s website. Page 5 of 7 2022 Anti-Doping Testing Figures – Executive Summary 2022 Anti-Doping Testing Figures Samples Analyzed and Reported by Accredited and Approved Laboratories in ADAMS Table 1: Total Samples Analyzed (All Sports) A Samples Analyzed Total Sport Analyzed AAFs 1 (%) ATFs 2 (%) Findings 3 (%) Olympic Sports 4 218,774 1,222 0.56% 316 0.14% 1,538 0.70% Non-Olympic Sports 5 37,995 764 2.01% 78 0.21% 842 2.22%

TOTAL 256,769 1,986 0.77% 394 0.15% 2,380 0.93% 1 The Adverse Analytical Findings (AAFs) in this report are not to be confused with adjudicated or sanctioned AntiDoping Rule Violations (ADRVs). "Adverse Analytical Finding" is defined in the World Anti-Doping Code as "A report from a WADA-accredited Laboratory or other WADA-approved Laboratory that, consistent with the International Standard for Laboratories and related Technical Documents, identifies in a Sample the presence of a Prohibited Substance or its Metabolites or Markers (including elevated quantities of endogenous substances) or evidence of the use of a Prohibited Method." These figures may not be identical to sanctioned cases (number of ADRVs), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process for example. 2 The Atypical Findings (ATFs) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRVs). "Atypical Finding" is defined in the World Anti-Doping Code as "A report from a WADAaccredited Laboratory or other WADA-approved Laboratory which requires further investigation as provided by the International Standard for Laboratories or related Technical Documents prior to the determination of an Adverse Analytical Finding." ATFs may correspond to multiple measurements performed on the same Athlete, such as in cases of longitudinal studies on testosterone. 3 Includes AAFs and ATFs. 4 Olympic sports in this table include sports reported into ADAMS and classified under ASOIF and AIOWF. 5 Non-Olympic sports in this table includes sports reported into ADAMS and classified as ARISF, AIMS, IPC, Sports for Athletes with an Impairment, other Sports from Code Signatories and Other Sports. These figures do not include blood samples taken for the ABP. ABP Blood samples can be found in the 2022 Anti-Doping Testing Figures - Athlete Biological Passport (ABP) Report - Blood Analysis.

Page 6 of 7 2022 Anti-Doping Testing Figures – Executive Summary 2022 Anti-Doping Testing Figures Samples Analyzed and Reported by Accredited and Approved Laboratories in ADAMS Table 2: Comparison of Years 2017 to 2022 - Olympic and Non-Olympic Figures reported in ADAMS 2017 2018 2019 2020 2021 2022 2022 vs 2021

A A A A A A

Samples Samples Samples Samples Samples Samples (% change) Analyzed Analyzed Analyzed Analyzed Analyzed Analyzed Olympic Sports 205,405 220,659 227,032 127,483 207,008 218,774 5.7% Non-Olympic Sports 39,827 42,860 51,015 22,275 34,422 37,995 10.4% TOTAL 245,232 263,519 278,047 149,758 241,430 256,769 6.4% 2017 2018 2019 2020 2021 2022 2022 vs 2021 AAFs AAFs AAFs AAFs AAFs AAFs (% change) Olympic Sports 1,575 1,659 1,519 612 1,013 1,222 20.6% Non-Olympic Sports 1,174 1,115 1,183 397 547 764 39.7% TOTAL 2,749 2,774 2,702 1,009 1,560 1,986 27.3% 2017 2018 2019 2020 2021 2022 2022 vs 2021 % AAFs % AAFs % AAFs % AAFs % AAFs % AAFs (% change) Olympic Sports 0.77 0.75 0.67 0.48 0.49 0.56 14.3%

Non-Olympic Sports 2.95 2.60 2.32 1.78 1.59 2.01 26.4% Overall 1.12 1.05 0.97 0.67 0.65 0.77 19.7% 2017 2018 2019 2020 2021 2022 2022 vs 2021 % Total % Total % Total % Total % Total % Total (% change) Findings Findings Findings Findings Findings Findings Olympic Sports 0.82 0.82 0.79 0.61 0.60 0.70 16.7% Non-Olympic Sports 3.02 2.74 2.53 2.00 1.81 2.22 22.7% Overall 1.18 1.13 1.11 0.82 0.77 0.93 20.8% Table 3: Summary - Total Samples Analyzed (ADAMS) Samples ATF AAF ADAMS Urine Total 231,313 381 1969 ADAMS Blood Total 22,708 13 13 ADAMS DBS Total 2,748 0 4 ABP Total 1 31,246 0 0 288,015 394 1,986 1 ABP total in Table 3 also includes ABP samples analyzed by WADA-approved Laboratories in Nairobi (Kenya) and Cairo (Egypt) - please refer to the ABP Report. Page 7 of 7 2022 Anti-Doping Testing Figures – Executive Summary 202 Anti-Doping Testing Figures 2

LABORATORY REPORT

2022 Anti-Doping Testing Figures 2022 Anti-Doping Testing Figures Samples Analyzed and Reported by Accredited Laboratories in ADAMS Table of Contents Total Samples Analyzed Table 1 : Summary - Samples Analyzed per Laboratory (as reported in ADAMS) Table 2 : Total IC and OOC Samples Analyzed per Laboratory (as reported in ADAMS)

Tests Conducted Table 3 : GC/C/IRMS Tests Conducted per Laboratory for Markers of the Steroid Profile (Urine) Table 4 : GC/C/IRMS Tests Conducted per Laboratory for 19-norandrosterone (Urine) Table 5 : GC/C/IRMS Tests Conducted per Laboratory for Boldenone (Urine) Table 6 : GC/C/IRMS Tests Conducted per Laboratory for Formestane (Urine) Table 7 : ESA Tests Conducted per Laboratory (Urine) Table 8 : ESA Tests Conducted per Laboratory (Blood) Table 9 : GHRF(GHS/GHRP) Tests Conducted per Laboratory (Urine) Table 10 : GHRF(GHRH) Tests Conducted per Laboratory (Urine) Table 11 : GnRH Tests Conducted per Laboratory (Urine) Table 12 : Insulins Tests Conducted per Laboratory (Urine and Blood) Table 13 : IGF-I Analogs Tests Conducted per Laboratory (Urine and Blood) Table 14 : hGH Isoforms Tests Conducted per Laboratory (Blood) Table 15 : hGH Biomarkers Tests Conducted per Laboratory (Blood) Table 16 : HBOC Tests Conducted per Laboratory (Blood and ABP Blood Samples) Table 17 : HBT Tests Conducted per Laboratory (Blood) Table 18 : Steroid Esters Tests Conducted per Laboratory (Blood) Substances Identified Table 19 : Summary - Substances Identified as AAFs in Each Drug Class in ADAMS (All Sports) Table 20 : Summary - Substances Identified as ATFs in Each Drug Class in ADAMS (All Sports) Table 21 : Substances Identified as AAFs in Each Drug Class in ADAMS (All Sports) Table 22 : Substances Identified as ATFs in Each Drug Class in ADAMS (All Sports) Table 23 : Total Laboratory AAFs per Drug Class as Reported in ADAMS (All Sports) Page 1 of 29 2022 Anti-Doping Testing Figures – Laboratory Report

2022 Anti-Doping Testing Figures Samples Analyzed and Reported by Accredited Laboratories in ADAMS Terms and Abbrevations IC In-Competition OOC Out-of-Competition Sample Any biological material collected for the purposes of Doping Control AAF Adverse Analytical Finding ATF Atypical Finding DBS Dried Blood Spot GC/C/IRMS Gas Chromatograph/Carbon/Isotope Ratio Mass Spectrometry (e.g."IRMS") ERA EPO-Receptor Agonists hGH Isoforms Human Growth Hormone Isoform Differential Immunoassay hGH Biomarkers Human Growth Hormone Biomarkers GHRF (GHS/GHRP) Growth Hormone Releasing Factors (Growth Hormone Secretagogues/GH-Releasing Peptides) GHRF (GHRH) Growth Hormone Releasing Factors (Growth Hormone Releasing Hormone) GnRH Gonadotrophin Releasing Hormones HBT Homologous Blood Transfusion HBOC Haemaglobin Based Oxygen Carrier IGF-I Insulin-like Growth Factor-I (and its analogues) ABP Athlete Biological Passport IOC International Olympic Committee ASOIF Association of Summer Olympic International Federations AIOWF Association of International Olympic Winter Sports Federations ARISF Association of IOC Recognized International Sports Federations AIMS Alliance of Independent Recognized Members of Sport NADO National Anti-Doping Organization RADO Regional Anti-Doping Organization NOC National Olympic Committee MEO Major Event Organization IF International Federation NF National Federation IPC International Paralympic Committee ADAMS Anti-Doping Administration and Management System TA Testing Authority SCA Sample Collection Authority - a "dash" represents "0" (no data) in tables compiling the number of Samples, ATFs or AAFs

A discipline which is discontinued in ADAMS based on request of the governing IF, being an event under an ( R ) existing discipline or being no longer necessary for administrative purposes Biological material limited to urine and blood in this report Including recombinant erythropoietins (i.e. epoetins) and their analogues (e.g. darbepoetin, pegserpoetin, peginesatide, CERA, EPO-Fc) Limited to sport/disciplines under the governance of the IPC (others are compiled under the category "Sports for Athletes with an Impairment"). This report compiles data as recorded in ADAMS on 20 Oct 2023 (plus supplemental data after Stakeholder consultation) Page 2 of 29 2022 Anti-Doping Testing Figures – Laboratory Report 2022 Anti-Doping Testing Figures Samples Analyzed and Reported by Accredited Laboratories in ADAMS Table 1: Summary - Samples Analyzed per Laboratory (as reported in ADAMS) Urine Blood 1 DBS Total ABP Total Laboratory Samples ATF AAF Samples ATF AAF Samples ATF AAF % AAF Samples2 Samples Ankara, Turkey 4326 16 24 195 - - - - - 0.53% 1490 6 ,011 Bangkok, Thailand 3 3314 8 65 49 - - - - - 1.93% 39 3 ,402 Barcelona, Spain 7139 22 59 420 - 1 - - - 0.79% 892 8 ,451 Beijing, China 13304 9 38 1373 - - 817 - - 0.25% 1863 1 7,357 Bloemfontein, South Africa 3761 29 80 158 - - - - - 2.04% 250 4 ,169 Bucharest, Romania 2819 3 20 445 - - - - - 0.61% 111 3 ,375

Cologne, Germany 23581 44 183 3329 1 1 272 - 2 0.68% 3936 3 1,118 New Delhi, India 3680 12 126 216 - 1 - - - 3.26% 168 4 ,064 Doha, Qatar 5803 12 80 843 - - - - - 1.20% 563 7 ,209 Dresden, Germany 11791 5 83 1084 1 - - - - 0.64% 1064 1 3,939 Ghent, Belgium 13869 5 100 1090 - 3 - - - 0.69% 1759 1 6,718 Havana, Cuba 5131 38 52 139 - - - - - 0.99% 86 5 ,356 Helsinki, Finland 2823 - 9 280 - - - - - 0.29% 509 3 ,612 Lausanne, Switzerland 11009 13 87 1403 1 - 977 - - 0.65% 2707 1 6,096 Lisbon, Portugal 4 426 3 3 37 - - - - - 0.65% 16 4 79 London, UK 9148 1 41 1406 - - - - - 0.39% 740 1 1,294 Los Angeles, USA 3 3854 14 61 - - - - - - 1.58% - 3 ,854 Madrid, Spain 4386 9 27 444 - - - - - 0.56% 1409 6 ,239 Montreal, Canada 10446 43 105 778 1 - - - - 0.94% 425 1 1,649 Oslo, Norway 3939 1 41 242 - 1 680 - 2 0.91% 1135 5 ,996

Paris, France 14374 11 110 1097 3 - - - - 0.71% 1791 1 7,262 Rio de Janeiro, Brazil 5143 3 45 429 - 1 - - - 0.83% 217 5 ,789 Rome, Italy 8916 5 78 1160 1 3 - - - 0.80% 788 1 0,864 Seibersdorf, Austria 20992 4 129 1809 1 1 2 - - 0.57% 1768 2 4,571 Seoul, Korea 3725 7 35 436 - - - - - 0.84% 244 4 ,405 Stockholm, Sweden 4421 1 41 134 - - - - - 0.90% 557 5 ,112 Sydney, Australia 5831 9 41 614 - - - - - 0.64% 665 7 ,110 Tokyo, Japan 6531 - 20 538 - - - - - 0.28% 555 7 ,624 Salt Lake City, USA 10489 50 125 2144 1 1 - - - 1.00% 3347 1 5,980 Warsaw, Poland 6342 4 61 416 3 - - - - 0.90% 775 7 ,533 Totals 2 31,313 381 1,969 2 2,708 13 13 2 ,748 0 4 0.77% 2 9,869 286,638 1 Blood Samples which are collected as venous blood in serum separator tubes or with anti-coagulants for analyses as whole blood or plasma. 2 ABP total does not include the ABP samples analyzed by the WADA-approved laboratories (please refer to ABP Report) 3 Not accredited to conduct blood analyses in support of the haematological module of the Athlete Biological Passport (ABP) in 2020.

4 Accredited 23 September 2022. 2022 Anti-Doping Testing Figures – Laboratory Report Page 3 of 29 2022 Anti-Doping Testing Figures Samples Analyzed and Reported by Accredited Laboratories in ADAMS Table 2: Total IC and OOC Samples Analyzed per Laboratory (as reported in ADAMS) Urine Blood DBS IC OOC IC OOC IC OOC Total Laboratory Samples ATF AAF Samples ATF AAF Samples ATF AAF Samples ATF AAF Samples ATF AAF Samples ATF AAF Samples Ankara, Turkey 2145 8 17 2181 8 7 33 - - 162 - - - - - - - - 4,521 Bangkok, Thailand 2508 5 54 806 3 11 42 - - 7 - - - - - - - - 3,363 Barcelona, Spain 4822 18 46 2317 4 14 117 - 1 303 - - - - - - - - 7,559 Beijing, China 4126 1 17 9178 8 21 151 - - 1222 - - 3 - - 814 - - 15,494 Bloemfontein, South Africa 2199 10 69 1562 19 11 42 - - 116 - - - - - - - - 3,919 Bucharest, Romania 1599 3 18 1220 - 2 133 - - 312 - - - - - - - - 3,264 Cologne, Germany 12064 30 140 11517 14 43 827 - 1 2502 1 - 250 - 2 22 - - 27,182 New Delhi, India 2280 10 90 1400 2 36 98 - - 118 - 1 - - - - - - 3,896

Doha, Qatar 3148 7 43 2655 5 36 345 - - 498 - - - - - - - - 6,646 Dresden, Germany 5410 1 58 6381 4 25 185 - - 899 1 - - - - - - - 12,875 Ghent, Belgium 6757 2 84 7112 3 16 242 - - 848 - 3 - - - - - - 14,959 Havana, Cuba 2624 19 45 2507 19 7 43 - - 96 - - - - - - - - 5,270 Helsinki, Finland 1421 - 7 1402 - 2 75 - - 205 - - - - - - - - 3,103 Lausanne, Switzerland 5121 7 64 5888 6 23 93 - - 1310 1 - 80 - - 897 - - 13,389 Lisbon, Portugal 199 1 3 227 2 - 24 - - 13 - - - - - - - - 463 London, UK 3406 - 26 5742 1 15 134 - - 1272 - - - - - - - - 10,554 Los Angeles, USA 1723 10 38 2131 4 23 - - - - - - - - - - - - 3,854 Madrid, Spain 2930 8 22 1456 1 5 94 - - 350 - - - - - - - - 4,830 Montreal, Canada 6177 17 80 4269 26 25 180 - - 598 1 - - - - - - - 11,224 Oslo, Norway 2167 - 32 1772 1 9 46 - - 196 - 1 382 - 2 298 - - 4,861

Paris, France 7325 7 90 7049 4 20 227 - - 870 3 - - - - - - - 15,471 Rio de Janeiro, Brazil 4249 - 34 894 3 11 159 - - 270 - 1 - - - - - - 5,572 Rome, Italy 4765 3 62 4151 2 16 211 - 1 949 1 2 - - - - - - 10,076 Seibersdorf, Austria 10451 3 96 10541 1 33 551 1 - 1258 - 1 - - - 2 - - 22,803 Seoul, Korea 1813 6 17 1912 1 18 101 - - 335 - - - - - - - - 4,161 Stockholm, Sweden 2416 1 33 2005 - 8 8 - - 126 - - - - - - - - 4,555 Sydney, Australia 2548 2 26 3283 7 15 63 - - 551 - - - - - - - - 6,445 Tokyo, Japan 2899 - 13 3632 - 7 160 - - 378 - - - - - - - - 7,069 Salt Lake City, USA 4845 40 82 5644 10 43 495 - - 1649 1 1 - - - - - - 12,633 Warsaw, Poland 3061 2 47 3281 2 14 80 - - 336 3 - - - - - - - 6,758 Totals 117,198 221 1,453 114,115 160 516 4 ,959 1 3 1 7,749 12 10 715 - 4 2 ,033 - - 256,769 Please refer to the ABP Report for IC and OOC ABP samples analyzed per Laboratory

2022 Anti-Doping Testing Figures – Laboratory Report Page 4 of 29 2022 Anti-Doping Testing Figures Samples Analyzed and Reported by Accredited Laboratories in ADAMS Table 3: GC/C/IRMS Tests Conducted per Laboratory for Markers of the Steroid Profile (Urine)

GC/C/IRMS

IC OOC Total Total % L aboratory Samples AAF Samples AAF Samples AAFs AAF Ankara, Turkey 53 - 80 - 133 - 0% Bangkok, Thailand 40 1 19 1 59 2 3.4% Barcelona, Spain 75 2 44 1 119 3 2.5% Beijing, China 74 - 146 - 220 - 0% Bloemfontein, South Africa 74 3 68 1 142 4 2.8% Bucharest, Romania 14 - 6 - 20 - 0% Cologne, Germany 149 6 185 5 334 11 3.3% New Delhi, India 13 - 16 - 29 - 0% Doha, Qatar 89 6 61 4 150 10 6.7% Dresden, Germany 67 4 84 1 151 5 3.3% Ghent, Belgium 224 4 229 3 453 7 1.5% Havana, Cuba - - - - - - n/a Helsinki, Finland 31 - 19 - 50 - 0% Lausanne, Switzerland 47 3 123 3 170 6 3.5% Lisbon, Portugal 1 - - - 1 - 0% London, UK 37 - 37 - 74 - 0% Los Angeles, USA 50 2 66 1 116 3 2.6% Madrid, Spain 78 - 32 - 110 - 0%

Montreal, Canada 154 1 101 - 255 1 0.4% Oslo, Norway 53 2 25 5 78 5 9.0% Paris, France 149 4 130 2 279 6 2.2% Rio de Janeiro, Brazil 29 6 66 4 95 10 10.5% Rome, Italy 214 5 198 4 412 9 2.2% Seibersdorf, Austria 227 - 208 4 435 4 0.9% Seoul, Korea 10 - 19 - 29 - 0% Stockholm, Sweden 22 2 17 1 39 5 7.7% Sydney, Australia 54 1 56 - 110 1 0.9% Tokyo, Japan 20 - 25 1 45 1 2.2% Salt Lake City, USA 207 3 129 1 336 4 1.2% Warsaw, Poland 60 2 98 - 158 2 1.3% Totals 2 ,315 57 2 ,287 42 4 ,602 99 2.15% Page 5 of 29 2022 Anti-Doping Testing Figures – Laboratory Report 2022 Anti-Doping Testing Figures Samples Analyzed and Reported by Accredited Laboratories in ADAMS Table 4: GC/C/IRMS Tests Conducted per Laboratory for 19-norandrosterone 1 ( Urine) GC/C/IRMS 19-norandrosterone IC OOC Total Total % L aboratory Samples AAF Samples AAF Samples AAFs AAF Ankara, Turkey - - - - - - n/a Bangkok, Thailand 2 1 1 - 3 1 33% Barcelona, Spain 1 - - - 1 - 0% Beijing, China - - - - - - n/a

Bloemfontein, South Africa - - - - - - n/a Bucharest, Romania - - - - - - n/a Cologne, Germany 30 5 4 - 34 5 15% New Delhi, India - - - - - - n/a Doha, Qatar - - - - - - n/a Dresden, Germany - - - - - - n/a Ghent, Belgium 4 1 1 - 5 1 20% Havana, Cuba - - - - - - n/a Helsinki, Finland - - - - - - n/a Lausanne, Switzerland 2 - - - 2 - 0% Lisbon, Portugal - - - - - - n/a London, UK - - - - - - n/a Los Angeles, USA - - - - - - n/a Madrid, Spain - - - - - - n/a Montreal, Canada 1 - 1 1 2 1 50% Oslo, Norway 1 - - - 1 - 0% Paris, France 1 1 - - 1 1 100% Rio de Janeiro, Brazil - - - - - - n/a Rome, Italy 14 8 7 5 21 13 62% Seibersdorf, Austria - - - - - - n/a Seoul, Korea 2 - - - 2 - 0% Stockholm, Sweden - - - - - - n/a Sydney, Australia - - - - - - n/a Tokyo, Japan - - - - - - n/a Salt Lake City, USA 1 1 - - 1 1 100% Warsaw, Poland - - - - - - n/a 59 17 14 6 73 23 31.5% 1 The test for 19-norandrosterone by GC/C/IRMS is a non-mandatory method and therefore not all Laboratories are required to have the capacity to perform this analysis.

Page 6 of 29 2022 Anti-Doping Testing Figures – Laboratory Report 2022 Anti-Doping Testing Figures Samples Analyzed and Reported by Accredited Laboratories in ADAMS 1 T able 5: GC/C/IRMS Tests Conducted per Laboratory for Boldenone (Urine) GC/C/IRMS Boldenone and/or metabolite(s) IC OOC Total Total % L aboratory Samples AAF Samples AAF Samples AAFs AAF Ankara, Turkey - - - - - - n/a Bangkok, Thailand - - - - - - n/a Barcelona, Spain 2 - 5 2 7 2 29% Beijing, China - - 2 - 2 - 0% Bloemfontein, South Africa - - - - - - n/a Bucharest, Romania - - - - - - n/a Cologne, Germany 15 4 14 - 29 4 14% New Delhi, India - - - - - - n/a Doha, Qatar - - - - - - n/a Dresden, Germany - - - - - - n/a Ghent, Belgium 3 1 2 - 5 1 20% Havana, Cuba - - - - - - n/a Helsinki, Finland - - - - - - n/a Lausanne, Switzerland - - - - - - n/a Lisbon, Portugal - - - - - - n/a London, UK - - - - - - n/a Los Angeles, USA - - - - - - n/a Madrid, Spain - - - - - - n/a Montreal, Canada 5 4 2 - 7 4 57% Oslo, Norway - - - - - - n/a Paris, France 6 1 9 2 15 3 20% Rio de Janeiro, Brazil - - - - - - n/a Rome, Italy 19 6 26 4 45 10 22%

Seibersdorf, Austria - - - - - - n/a Seoul, Korea 1 - 1 1 2 1 50% Stockholm, Sweden - - - - - - n/a Sydney, Australia - - - - - - n/a Tokyo, Japan - - 1 1 1 1 100% Salt Lake City, USA 2 1 3 3 5 4 80% Warsaw, Poland - - - - - - n/a Totals 53 17 65 13 118 30 25.4% 1 The test for Boldenone by GC/C/IRMS is a non-mandatory method and therefore not all Laboratories are required to have the capacity to perform this analysis. Page 7 of 29 2022 Anti-Doping Testing Figures – Laboratory Report 2022 Anti-Doping Testing Figures Samples Analyzed and Reported by Accredited Laboratories in ADAMS 1 T able 6: GC/C/IRMS Tests Conducted per Laboratory for Formestane (Urine) GC/C/IRMS Formestane IC OOC Total Total % L aboratory Samples AAF Samples AAF Samples AAFs AAF Ghent, Belgium 1 - 1 - 2 - 0% Paris, France 2 - - - 2 - 0% Rio de Janeiro, Brazil 1 - - - 1 - 0% Rome, Italy - - 1 - 1 - 0% Totals 4 0 2 0 6 01 The test for Formestane by GC/C/IRMS is a non-mandatory method and therefore not all Laboratories are required to have the capacity to perform this analysis. Page 8 of 29 2022 Anti-Doping Testing Figures – Laboratory Report 2022 Anti-Doping Testing Figures Samples Analyzed and Reported by Accredited Laboratories in ADAMS Table 7: ERA Tests Conducted per Laboratory (Urine)

ERAs [including erythropoietin (EPO) and other EPO-receptor agonists] Urine IC OOC Total % L aboratory Samples AAF Samples AAF Samples AAFs AAF Ankara, Turkey 294 - 561 - 855 - 0% Bangkok, Thailand 465 1 167 - 632 1 0.2% Barcelona, Spain 718 1 551 - 1269 1 0.1% Beijing, China 1049 - 2142 1 3191 1 0% Bloemfontein, South Africa 471 1 421 - 892 1 0.1% Bucharest, Romania 269 1 300 - 569 1 0.2% Cologne, Germany 2083 2 3759 - 5842 2 0.0% New Delhi, India 370 9 244 2 614 11 1.8% Doha, Qatar 680 1 859 3 1539 4 0.3% Dresden, Germany 1254 - 2028 1 3282 1 0.03% Ghent, Belgium 1670 2 1857 1 3527 3 0.1% Havana, Cuba 483 - 647 1 1130 1 0.1% Helsinki, Finland 170 - 409 - 579 - 0% Lausanne, Switzerland 827 3 1924 3 2751 6 0.2% Lisbon, Portugal 53 - 66 - 119 - 0% London, UK 323 1 1533 - 1856 1 0.1% Los Angeles, USA 134 - 516 - 650 - 0.0% Madrid, Spain 885 2 460 - 1345 2 0.